Tagged with USA

USA Jorge Alderete, president of ALK Americas, outlines the Danish mid-cap’s strategy in the challenging US market, including innovative market access initiatives, and how future models of patient-doctor interaction and medical distribution will look.   Affordability is key. We recently launched a specialty pharmacy network for our portfolio. This allows us…

Cell & Gene Therapy A full list of the cell and gene therapy products approved by the US FDA. Made with Visme Infographic Maker  

USA Carol Lynch, president of Sandoz US and head of Sandoz North America, recently spoke exclusively to PharmaBoardroom about how her diverse global experiences in innovative biopharma and biosimilars are informing her leadership strategy in the US generics space. Lynch also outlines how greater uptake of biosimilar medicines can be fostered…

USA Carol Lynch of Sandoz US talks candidly on the US generics market from an international perspective, market access, biosimilars uptake, talent attraction, and navigating the COVID-19 crisis.   The US is the largest generics market in the world, so it is an absolutely key market for Sandoz, representing around 26…

Opinion DataArt’s Daniel Piekarz looks at how machine learning and artificial intelligence can play into the important task of drug repurposing, potentially providing solutions to the most pressing healthcare concerns of today, including the COVID-19 pandemic.   “Standing on the shoulders of giants” is a metaphor, made famous by Isaac Newton,…

USA Aldo Donati, CEO for Swiss firm IBSA in the USA, discusses the challenges for European mid-caps in expanding to the US market and his portfolio strategy for ensuring future successes for IBSA USA.   In the global economy we are operating in, the US market cannot be ignored and if…

Opinion Dr Neil Cashman examines the recent news around Biogen’s Alzheimer’s treatment aducanumab, assuages some investor fears, and underlines the treatment’s solid fundamentals and potential.    On April 2020, Biogen initiated regulatory review for aducanumab, its investigational therapy for Alzheimer’s disease. Investors reacted negatively, and this reverberated throughout the Alzheimer’s research…

USA So far in 2020 PharmaBoardroom has conducted interviews with several key stakeholders in US healthcare. We have heard from leaders the US FDA, as well as representatives of patient groups, health insurance providers, and firms operating in the US on what they consider the most pressing issues facing US healthcare.…

USA US healthcare is often seen as a fragmented system of contrasts. The country has the highest healthcare expenditures as a percentage of GDP and the highest drug prices in the OECD, supporting the largest and most innovative healthcare market globally. However, it also has shockingly subpar healthcare outcomes compared to…

Coronavirus Takeda’s Head of R&D Patient Engagement Jessica Scott examines the parallels between partnering with patients and working remotely with colleagues in the time of COVID-19.   Patients need us to engage with them, ask questions and listen. Just as we’re experiencing now with our own work relationships with colleagues, deeper…

USA Marc Boutin, JD, CEO of the National Health Council (NHC),* introduces the organization and its mission to provide a united voice for the 160 million people in the US living with chronic diseases and disabilities and their family caregivers. He addresses the challenge faced by patients living with chronic diseases…

USA Robert Matsuk, president of Glenmark North America, introduces the scope of the company’s operations in the US – including a manufacturing facility that obtained its first approval in 2019. Matsuk describes the unique business model a generic player in the US needs to maintain its competitiveness and conveys the role…